EP4 agonists have reduced bronchodilation activity in patients with Group III pulmonary hypertension
Xavier Norel(Inserm), Dan Longrois(Hôpital Bichat-Claude-Bernard), Adam M. Silverstein(United Therapeutics (United States)), Andrew C. Nelsen(Triangle), Richard Bayles(Inserm), Lucie H. Clapp(The London College), Gülsev Özen(Istanbul University), Yves Castier(Université Claude Bernard Lyon 1), Hervé Mal(Université Claude Bernard Lyon 1), Chabha Benyahia(Inserm)
Proceedings for Annual Meeting of The Japanese Pharmacological Society
January 1, 2018
Cited by 0
Related Papers
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
Comfort and patient-centred care without excessive sedation: the eCASH concept
|Intensive Care Medicine|2016|429
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
Terlipressin for norepinephrine-resistant septic shock
|The Lancet|2002|259
Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study
|The Lancet Respiratory Medicine|2021|254